Children's Cancer

We are proving the thesis for the industry that including children is the right thing to do for patients, buts also the right things to do for shareholders. We get calls from companies that say, hey, we may not want a partner or product, but we're trying to figure out how to do this in children. And i'm very hopeful that hopefully, you know, we'll be able to nlicense more ics. I love that we've, we've brought in two meck inhibitors. That's validation that we can do it again. There are more medicines out there that have the potential to help both children and adults. But what's cropped up recently are smaller consertia